Lilly Adds Ethics Watchdogs To Settle Lawsuits
19 CommentsBy Ed Silverman // March 9th, 2010 // 12:58 pm
The drugmaker is adding four new senior positions to “promote highly ethical and compliant behaviors” as part of a settlement of two shareholder lawsuits stemming from off-label promotion of its Zyprexa antipsychotic and other drugs. You may recall that last year, Lilly paid $1.4 billion to settle criminal and civil complaints (see here).
Lilly is also upgrading policies and procedures “to ensure that objective scientific inquiry, analysis and communication in matters affecting patient safety and benefit shall be of paramount importance,” according to a filing with the Securities and Exchange Commission. The shareholder suits claimed the drugmaker breached its fiduciary duty and Lilly agreed to pay about $8.7 million to settle.
The new positions being created are vice president of global ethics, vice president for global compliance strategy, a senior director of enterprise risk management and a project manager to implement and monitor the new policies. All four will report to Anne Nobles, Lilly’s chief ethics and compliance officer. Merck took similar steps recently to settle shareholders suits, including hiring a chief medical officer (see here).
Other steps include: ensuring that every Lilly product on the market and every drug entering large-scale development will have a Product Safety Physician responsibile for safety issues throughout that product’s life cycle. Lilly’s ceo and board must meet at least one a year with the chief ethics and compliance officer to review accountability and related procedures.
Hat tip to The Indy Star
SteveM
Eli-Lilly is a criminal enterprise. Those new VP’s are window dressing. Nobles didn’t and doesn’t need a new layer of management to tell her and Lilly how not to be creeps.
“vice president of global ethics” Hah! That’s like Tony Soprano naming Pauli Walnuts “vice president of family ethics”.
Industry Guy
Two more golden parchutes to fill with salaries from the laid off…..
Doc
Pretty pathetic that “ethical pharma” has come to this.
As long as sales reps are incentivized by cash bonuses, exotic award trips, prizes, contests and told if they fall into the bottom 10% (thank you Jack Welch) they will be fired, outrageous behaviour will continue. The marketing and sales admin are even more responsible, as much of the “ideas” and pressure to “sell” comes from them.
When (or) will the industry put patient well being at the forefront of their efforts?
Profits and patient welfare are not mutually exclusive.
Melody
I rarely post here anymore. My cynicism has just about maxed out where BigPharma is concerned. But Ed must know that pointing to Lilly’s bad behavior is like waving a red flag in front of a bull.
I truly believe that Lilly is not only criminal (see above comment) but purely evil . . . and I think they plotted the roadmap followed by so many other BigPharma players today—profit before patients, executive pay/perks off the top, and paltry offerings that oftentimes are little more than another me-too product.
Almost 3 decades ago, when Lilly proponents wanted to be the first biotech marketer, what they did to the patient base, is remarkable. They produced rDNA insulin; got it to market with the scantest of research (it only had to lower blood sugar and not kill the patient immediately), and wrote the book on market manipulation. Because they were their own primary competitor (natural insulin producer and rDNA producer), they did indeed manipulate the market, but no patients could ever convince the FTC or SEC that this was a fact. They literally removed the competition by withdrawing their OWN time-proven natural insulins, supplanting them with genetically-engineered insulin. (Interesting coincidence was the subsequent actions of Novo . . . who to all appearance merely ‘followed the leader.’) rDNA insulin was never shown to be superior—or even as good as—the product god or evolution (pick your belief system) created within another biological entity. Because of the sad state (and voluntariness) of the FDA’s adverse event reporting mechanism, the number of patients who were harmed or died is unknowable . . . and conveniently, diabetes and patient non-compliance could always be used to explain unexpected tragedies.
Lilly (in my opinion) is a world-class leader . . . and considering the malfeasance that is almost a daily occurrence within BigPharma, that is NOT a compliment.
M Helm, MD
I wonder what the jobs pay? Looks kind of like the equivalent of a “no-show” job to me. Could be a nice gig if you didn’t take it seriously at all. Likely a “non-serious” attitude about the work would be a welcome philosophy from the perspective of the board and the CEO.
Why do you suppose that these wrist-slap judgements and paltry ($1.4 Billion paid once is pretty insignificant to the annual stream of now about $5 billion) to insulting ($8.7 million) financial settlements continue to be acceptable practice?
It is really hard to see how the shareholders were “injured” in this. Lilly has maintained a reserve for paying out for their ethically/legally out-of-bounds behavior on Zyprexa and other products for many years. It is not like any of this was a surprise to anyone who could read their annual report (shareholder or not). Lilly stock tanked in Oct 2008, rebounded in late December 2008 and maintained a nice plateau in January 2009 (which was when the big settlement was announced). Since then the stock went down again in March 2009, but has been pretty steady since then floating around $35 per share. In other words, the overall market trends have affected Lilly’s stock, but the “big” settlement was barely a blip - in fact, it didn’t move the stock from a high point in the month it was announced.
Former Pharma Marketing Director
Hey Doc,
You are right “Profits and patient welfare are not mutually exclusive”. But unfortunately many Big Pharma companies think this is the case.
If people wouldn’t constantly play with pharma, i.e. accept help from marketing on preparing presentations, attend Global CME events, speaker honorariums, seeder trial research money, and the list goes on, then marketing would dry up and we could get back to the business of looking after the patients….
The medical department should run the organization under the supervision and care of some VP MBA’s to make sure the money is used wisely.
Get rid of marketing, add more ethicists,scientists and doctors…
But we are just preaching to the converted here…
Justice in MI
Well, I suppose I’m one of the converted, but I want to hold out a fig leaf of hope, even though Lilly happens to be directly, and feloniously, responsible for the death of people as close to me as it gets.
Braithwaite has written great stuff on ethics officers of this sort. But the bottom-line is not complicated. It it is, indeed, a fig leaf, everyone in the company knows it, and knows it immediately. If there are teeth and substance in a way that has to potential to reinvent a company’s moral culture, it can be a different thing.
I’m not betting on the latter, but there are too many people who’ve already died in vain for me to presume, exclusively, the former.
Sam Worthington
We found that there are many legit foreign pharmacies that provide for safe and reliable medications at much lower prices. The idea that only US pharmacies can provide quality medications like vicodin, hydrocodone, norco, lorcet is obviously shallow. Foreign internet pharmacies will also often offer their patients a free online consultation. It would not be hard for authorities to recommend the use of such pharmacies to patients in need, but instead the DEA insist that the consumers’ safety is at stake when ordering at foreign pharmacies, since the safety can be compromised due to falsification and adulteration of the pharmaceutical products available in other countries is indicated findrxonline in article on pharmacies online.
Former Pharma Marketing Director
I have been giving some more thought to this.
I am on the path toward bio ethics myself, and it would be a dream to go back to Pharma as an ethicist with marketing background.
It will be interesting to see if the ethicist can stay on the ethical path and actually convince the executive to forgo short term sales gain in order to accrue long term growth stability unencumbered by lawsuits, legal fees and fines.
Hmm, might have to dust off my cv….
Josh
Does Nobles report through the board or through the CEO? I would think that the people in these positions would have more teeth if they didn’t report through the CEO or “upper management”.
elmore
Was Nobles around when the bad stuff was going on?
pharmavet
I agree with FPMD about Pharma getting out of the business of CME. However, without Pharma support, future medical meetings will look something like the following:
1) meeting will be switched from midwinter Orlando to midwinter in Chicago, to take advantage of off-peak hotel rates, where the average daily temp is about 18 degrees F.
2) no more 6AM satellite symposium with full breakfast of eggs benedict, pancakes, Canadian bacon, sausage, warm rolls, Bananas Foster, Crepes Fitgerald and capuccino. To be replaced by a cold bagel and lukewarm Maxwell House Coffee.
3) no more outings with the wife to Sea World (killer whales notwithstanding).
4) no more wine tasting events.
5) no more truffles on the pillow to greet incoming guests.
5) filet mignon at dinner to be replaced by round steak.
6) no more great musical entertainment (we had The Eagles in 1993 for a $300K set).
7) no more jetting 300 doctors and wives to Cancun or San Diego for an all-expense paid launch meeting for a new drug.
8) no more golf on Kiawah Island or jet skiing in Florida on the company.
9) no more discounts on medical textbooks or audiotapes.
10) no more “Meet the Professor” over fondue to discuss latest research.
I’m not one for perks, but some of the above changes paint a fairly realistic picture of what the loss of Pharma support will mean to CME.
Justice in MI
Former–Write if you get work! I think it’s a terrific idea. Can I tag along? Sort of a Vice Ethicist (contradiction in term?)
Vet–I have a feeling the killer whale may still be permitted.
Jack Friday
http://pharmagossip.blogspot.com/2010/03/lolpharma-contd-call-me-tony.html
Enjoy!
Big Pharma Watch
What an incredible joke! Like many other Big Pharma companies, these new positions at lilly will no doubt be powerless when up against the commercial machine! Sadly, ethics and Big Pharma are like oil and water - they don’t mix. With all the greedy non-medical, non-scientific, non-caring MBAs running the ship, it will never change. indict them, try them, fine them, jail them, and then throw away the key. maybe then, and only then, will the crimes against humanity stop!
Former Pharma Marketing Director
Pharmavet, that is a rather detailed list of things that will be cut, but I notice that since the actual education part wasn’t on the list, then that would still be available, unless of course you are insinuating that it can’t be cut, because it really isn’t there anyway ;-)
JIM - yeah, I’ll let you know if they would hire me….You can certainly tag along…Vice Ethicist - Ha you are so funny, between Ed’s picture logo for the FDA, Pharmavets list of things to be cut if marketing pulls out of CME and your vice ethicists remark, I am laughing like crazy, probably disturbing my fellow researchers close by, I have to go for a walk and laugh hysterically - thanks.
Oh and Salmon, yeah a logo of Don Corleone for the FDA - precious, precious…..
OMG, somebody just asked me to stop laughing….
pharmavet
FPMD, they can’t cut the education piece, or else there would be no CME credit.
Former Pharma Marketing Director
Yes of course Pharmavet, I was being facetious, it was just that kind of day….
Mindf&@$ed
I am very polite and enjoy a well pressed pair of slacks.